Gert Jan Oplaat, president of the AVEC, the Association of European Poultry Producers (essentially the equivalent of USPOULTRY and the USAPEEC combined) recently called for international coordination on control of HPAI including vaccination in accordance with the recommendations and policies of the World Organization of Animal Health (WOAH).
Oplaat, a leader of his native Dutch poultry organization emphasized, “The pandemic status of HPAI with outbreaks of H5N1 clade 2.3.4.4.b has continued for over the past four years”. He correctly drew attention to the financial impact of mass depopulation, escalation in the cost of products to consumers and the potential risk to public health following the possible emergence of a zoonotic strain. Current stamping-out campaigns are regarded as a “waste of resources” and the approach is antithetical to sustainability, welfare and a favorable public perception of the poultry industry.

A number of nations have implemented vaccination as a prevention and control measure supplementing biosecurity and quarantine. EGG-NEWS recently commented on the successful reduction in the incidence of outbreaks of HPAI within the foie gras industry of France. Farmers operate in close proximity often with defective biosecurity, allow outside access of flocks creating susceptibility by exposure to HPAI infection from migratory birds and by wind-borne dissemination of virus. Our southern neighbor has employed vaccination as a control strategy to reduce the spread and economic consequences of uncontrolled HPAI. China has deployed vaccination for over a decade to limit flock infection and to reduce exposure to consumers through wet markets.
The current restraints to deploying commercially available and effective vaccines relate not to efficacy but to the reality of trade sanctions. Effective vaccines to protect flocks against H5N1 HPAI include live vectored products for mass immunization and inactivated oil emulsion DIVA vaccines for parenteral administration.
Stamping-out has failed to eliminate the endemic status of HPAI in Europe and North America. The infection is introduced by migratory and marine waterfowl and disseminated by contact with free-living birds and the aerogenous route. This has raised questions as to the validity of current control measures. Regulators in importing nations have been slow to accept the benefits of vaccination, adhering to traditional pre-panornitic regulations. The representations by AVEC reflect the realities of trade restrictions that are now anachronistic and epidemiologically invalid given available programs of surveillance and certification. Oplaat correctly states that “HPAI is not only a trade issue, it is a long-term structural challenge for animal health, sustainability and credibility.”

The EU will produce 11.970 million metric tons of RTC chicken in 2026. Of this total, 1.720 million metric tons or 14 percent will be exported. This figure is offset by imports of 0.8 million metric tons, principally from Brazil, Ukraine and Thailand. Corresponding figures for the U.S. comprise 22.090 million metric tons of RTC broiler production in 2026 with 3.052 million metric tons exported representing 13.8 percent of production.
AVEC recommends the following approach to vaccination: -
- Targeted application to high-risk species including ducks, turkeys and long-lived egg production and breeder flocks.
- Concentration on regions demonstrating a history of reoccurring seasonal outbreaks.
- Implementation of accepted epidemiologically sound surveillance protocols.
- Selection of vaccines based on efficacy and incorporating the DIVA principle.
- Transparent sharing of data.
- Conformity to WOAH standards regarding vaccine quality, monitoring of immunity and reporting outbreaks.
- Acceptance of vaccination with surveillance and certification by the World Trade Organization that should suppress unjustified import restrictions to protect domestic industries.
Ultim
ately vaccination will be accepted but to facilitate the process, AVEC recognizes the need for common standards supported and promoted by the International Poultry Council (IPC) and the World Egg Organization. Setting aside competition among exporting nations, dialog is essential to establish uniform standards and regulations relating to vaccines, vaccination, surveillance, certification and reporting, all in conformity with WOAH directives. It is evident that the IPC should serve as a coordinating body and establish leadership. To date HPAI has not been a major problem in the broiler industries of the U.S. and Brazil, the world’s leading exporters. Both nations have maintained production and trade despite heavy losses in the U.S. duck, turkey and egg production sectors.
Oplaat correctly states that a coordinated program of controlled vaccination would send a signal to manufacturers of biologics to invest in both research and production capacity to supply the resulting demand for avian influenza vaccines. The biopharmaceutical industry has been constrained by a patchwork of regulations and evident hostility towards immunization based on scientifically unsubstantiated fears of obstruction to export of raw chicken and turkey products.
Until the emergence of genotype-VI avian paramyxovirus, clinical Newcastle disease was successfully prevented by application of a range of live and inactivated vaccines. Avian influenza is effectively the “Newcastle disease of the 2020s” since it represented as much of a challenge in the 1970s to production and trade as HPAI in the 2020s.
AVEC has taken the initiative to motivate a collective approach to regulating vaccination to prevent outbreaks of avian influenza in the interest of poultry producers, consumers and public health. The organization is actively advocating for the abolition of unjustified trade restrictions. It is now up to the IPC and IEC following the AVEC lead, to remove restrictions limiting tactical application of immunization of high-risk poultry segments in historically affected regions.